Skip to main content

Table 8 Oncologic outcomes of fertility-sparing surgery after NACT (where N > 5 reported)

From: Fertility-sparing management in cervical cancer: balancing oncologic outcomes with reproductive success

Study N who received NACT Timing of LN assessment
(N positive LN)
NACT regimen Surgical procedure N recurrence (mos) N dead of disease (mos) Median follow up months for entire series (range)
Maneo 2008 [65] 21 After NACT (2) TIP/TEP x 3 Cone 0a 0 69 (10–124)
Robova 2010 [132] 15 After NACT (1) TI/TAx3 ST 3 (−) 1 (−) 76.5 (17–142)
Marchiole 2011 [64] 7 After NACT (0) TIP/TEP x2-3 VRT 0 0 22 (5–49)
Vercecllino 2012 [133] 6 Before NACT (0) 1-TP
5-TIP
VRT 0 0 30.6 (8–70)
Lanowska 2014 [134] 20 Before NACT (0) TIP/TP × 2-3 VRT 1 (20) 0 23 (1–88)
Salihi 2015 [131] 11 Before NACT (1) 2 TIP x3
4 ddCP x3
5 wCP x3
Cone 1 (40) 0 58 (13–122)
Total N = 80     N = 5 N = 1  
Crude rates (%)      Recurrence rate = 6.3 %# Mortality rate = 1.3 %#  
  1. Abbreviations: NACT neoadjuvant chemotherapy, LN lymph node, ST simple trachelectomy, VRT vaginal radical trachelectomy, TP cisplatin + paclitaxel, TI cisplatin + ifosfamide, TA cisplatin + doxorubicin (for adenocarcinoma), TIP cisplatin + paclitaxel + ifosfamide, TEP cisplatin + paclitaxel + epirubicin (for adenocarcinoma), ddCP dose dense carboplatin + paclitaxel, wCP weekly carboplatin + paclitaxel
  2. #Crude recurrence and mortality rates among those who successfully underwent fertility sparing surgery, notwithstanding adjuvant treatment received
  3. a N = 3 patients developed CIN in the residual cervix